AI Market Mood: Stock Dashboard
PFE
Fundamental
Technical:
Latest News:
Pfizer Continues Cancer Rally as Adectris Label Expands to Non-Hodgkin Lymphomas somewhat bullish
PFE
Summary: Pfizer's antibody-drug conjugate Adcetris has received FDA approval for treating certain non-Hodgkin lymphomas, increasing its total number of indications to eight. The expansion allows the drug's use with lenalidomide and rituximab after two lines of systemic therapy in specific patients with large B-cell lymphoma who are not eligible for stem cell transplantation or CAR T therapy.
Full articleUSFDA approves Pfizer Adcetris combination regimen for Relapsed/Refractory Diffuse ... very bullish
PFE
Summary: Pfizer Inc. receives FDA approval for the supplemental BLA for ADCETRIS in combination therapy for the treatment of relapsed or refractory large B-cell lymphoma, showing significant improvement in overall survival based on Phase 3 study. The therapy provides a new option for patients who have failed two prior lines of therapy.
Full articlePfizer's Recent Gains Highlight Market Volatility and Sector Performance Disparities somewhat bearish
PFE
Summary: Pfizer has recently undergone a revision in its stock evaluation following a decline of 3.02% on December 31, 2024, suggesting a potential shift in market dynamics. Despite the recent performance dip, the stock continues to trade above certain moving averages.
Full articlePfizer Gains 6%; BSE HEALTHCARE Index Up 1.3% Thu, 13 Feb 10:51 - Equitymaster very bullish
PFE
Summary: Pfizer stock price surges by 6%, BSE HEALTHCARE Index up by 1.3% with notable gainers being SUVEN PHARMACEUTICALS and Aurobindo Pharma, Pfizer's net profit drops YoY, BSE Sensex and NSE Nifty show positive movements.
Full articlePfizer call volume above normal and directionally bullish - Markets Insider very bullish
PFE
Summary: Bullish option flow detected in Pfizer (PFE) with high call volume and increasing implied volatility. Most active options are Feb-25 25 calls and 2/28 weekly 25 puts. Earnings are expected on May 7th.
Full articleU.S. FDA Approves Pfizer's ADCETRIS® Combination Regimen for the treatment ... - Yahoo Finance very bullish
PFE
Summary: Pfizer's ADCETRIS regimen receives FDA approval for adult patients with relapsed or refractory large B-cell lymphoma, demonstrating a 37% reduction in the risk of death. This marks the eighth FDA-approved indication for ADCETRIS, positioning it as a standard of care for certain lymphomas.
Full articleU.S. FDA Approves Pfizer's ADCETRIS® Combination Regimen for the treatment ... - Business Wire very bullish
PFE
Summary: Pfizer Inc. announced that the FDA has approved ADCETRIS in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of therapy. The approval is based on positive efficacy and safety data from the Phase 3 ECHELON-3 study.
Full articlePfizer call volume above normal and directionally bullish - TipRanks.com very bullish
PFE
Summary: Bullish option flow detected in Pfizer (PFE) with significant call trading volume and increased implied volatility. Most active options include Feb-25 25 calls and 2/28 weekly 25 puts. Earnings expected on May 7th.
Full articleREG - Goldman Sachs Intl Pfizer Inc Haleon PLC - Proposed Offering of Ordinary Shares in ... neutral
PFE
Summary: Pfizer Inc. intends to sell approximately 540 million ordinary shares in Haleon plc, representing approximately 5.9% of Haleon's issued share capital, through an accelerated bookbuilding process. The completion of the offering will be followed by a share buyback agreement where Haleon will purchase shares from Pfizer.
Full articlePfizer intends to sell about 540M ordinary shares in Haleon - TipRanks.com somewhat bearish
PFE HLN
Summary: Pfizer (PFE) announces intention to sell approximately 5.9% of Haleon plc's issued share capital through an accelerated bookbuilding process to institutional investors.
Full articleAnalysis Group Provides Support for Ranbaxy and Pfizer in Defeat of Lipitor Reverse ... somewhat bullish
PFE OTRK
Summary: Analysis Group provided expert testimony in a long-running antitrust case involving Pfizer and Ranbaxy's alleged delayed market entry for generic Lipitor, ultimately resulting in the court denying plaintiffs' motions for certification and granting defendants' motion for summary judgment.
Full articlePfizer introduces a new breakthrough for acute migraine relief in the UAE, aiming to ... very bullish
PFE
Summary: Pfizer launching a new breakthrough for acute migraine treatment with a nasal spray that provides pain relief in as early as 15 minutes.
Full article